HCPCS code Q2056
Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
What Q2056 means
Q2056 (Ciltacabtagene car-pos t) belongs to the HCPCS Level II Q series (Temporary Codes). Its Medicare coverage status is Carrier judgment. Medicare coverage is left to the judgment of the local Medicare Administrative Contractor (MAC), so check your MAC's local coverage determinations.
Part B pricing: Drugs.
Code details
- Short description
- Ciltacabtagene car-pos t
- Coverage code
- C = Carrier judgment
- Pricing indicator
- 51 = Drugs
- Multiple pricing indicator
- A = Not applicable as HCPCS priced under one methodology
- Type of service
- 1 = Medical care P = Lump sum purchase of DME, prosthetics, orthotics
- Action code
- N = No maintenance for this code
- Action effective date
- October 01, 2022
- Code added date
- October 01, 2022
- Data year
- 2026
Questions about Q2056
What is HCPCS code Q2056?
HCPCS code Q2056 is a Level II code in the Q series (Temporary Codes). Its full description is: "Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose"
Is Q2056 a CPT code?
No. Q2056 is a HCPCS Level II code maintained by CMS, not a CPT (Level I) code from the American Medical Association. People often search for it as a CPT code because both code sets are reported on the same claims.
Does Medicare cover HCPCS code Q2056?
The Medicare coverage code for Q2056 is "Carrier judgment". Medicare coverage is left to the judgment of the local Medicare Administrative Contractor (MAC), so check your MAC's local coverage determinations.
When was HCPCS code Q2056 added?
Q2056 was added to the HCPCS code set on October 01, 2022. The most recent action on it (No maintenance for this code) took effect on October 01, 2022.
Nearby Q codes
All Q codes- Q2050Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
- Q2052Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)
- Q2053Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2054Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2055Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2057Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2058Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
- Q3001Radioelements for brachytherapy, any type, each
- Q3014Telehealth originating site facility fee
- Q3027Injection, interferon beta-1a, 1 mcg for intramuscular use